Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective randomized study of modified Vunakizumab maintenance dosing in moderate to severe plaque psoriasis
ChiCTR2600124819Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of vunakizumab in plaque psoriasis (3 arms), sponsored by Huashan Hospital. Primary endpoint: Proportion of participants maintaining PASI 75 at week 60. Planned start May 2026; status: not yet recruiting.
02
Drugs
vunakizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2600124819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124819.